Inhaled Albuterol Recalled — Physician’s First Watch

Medical News |
October 18, 2013

Inhaled Albuterol Recalled

By the Editors

Ten lots of albuterol inhalation solution (0.083%) are being voluntarily recalled "as a precautionary measure" because of findings from the manufacturer's internal monitoring processes.

The company, Nephron Pharmaceuticals Corporation, does not specify what was found during its "aseptic process simulation," but it advises consumers to stop using albuterol from the affected lots (the lot numbers are listed in the company's press release).

No adverse events have been reported.

Reader Comments (3)

Vera M Davis(asthma patient) Other, retired

I am reporting the affects of this lot recalled.I have been using Ambuterol for 7yrs and this the first time I noticed something different about this RX 10/11/2013. I have a fine rash all over my body and itching of my scalp and body constantly...I did id the recall as the same I have been using since 10/11/13. There is also a choking cough...why are there no reasons reported to warn patients of what to expect?

Jerome B Kaufman, MD, FACS, FICS Physician, Surgery, Specialized, Retired Neurosurgeon; Clinical Professor, Emeritus

History of chronic COPD

Dong Duong, MD Physician, Family Medicine/General Practice, Kaiser

Very informative, useful

Your Comment

(will not be published)

Filtered HTML

  • Allowed HTML tags: <a> <em> <strong> <cite> <blockquote> <code> <ul> <ol> <li> <dl> <dt> <dd>
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Do you have any conflict of interest to disclose?
This question is for testing whether you are a human visitor and to prevent automated spam submissions.
Enter the characters shown in the image.

Vertical Tabs

* Required

Reader comments are intended to encourage lively discussion of clinical topics with your peers in the medical community. We ask that you keep your remarks to a reasonable length, and we reserve the right to withhold publication of remarks that do not meet this standard.

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.